119356-77-3 Men Sexual Health , Raw Medical Material Powder for Male Sex

is a short-acting selective serotonin-reuptake inhibitor (SSRI). It is the first pharmacological treatment for premature ejaculation to be licensed in the UK. In a pooled analysis of 4 randomised controlled trials (RCTs) in men with premature ejaculation there was a statistically significant increase in intravaginal ejaculatory latency time (IELT) with on demand compared with placebo on demand, although an increase in IELT was also seen with placebo.

- Statistically significant increase in IELT from baseline with 30 mg and 60 mg on demand compared with placebo on demand (from 0.9 minutes in all groups to 1.9, 3.1 and 3.6 minutes respectively for placebo, 30 mg and 60 mg; p<0.001 for comparisons with placebo, pooled analysis of 4 RCTs, n=4843).

- Statistically significantly more men reported that their premature ejaculation was etter or much better with compared with placebo (30.7% and 38.3% with 30 mg and 60 mg respectively compared with 13.7% with placebo; p<0.001 for comparisons with placebo, pooled analysis of 4 RCTs, n=4843).

- Orthostatic hypotension and syncope was reported in clinical trials and the summary of product characteristics includes recommendations to minimise the risk of this.

- Treatment with should not be initiated with the 60 mg dose. The incidence and severity of adverse events is higher with the 60 mg dose.

- Men will need to be appropriately assessed and given an accurate diagnosis of premature ejaculation in line with the indication in the summary of product characteristics before can be considered.

- is taken on demand approximately 1 to 3 hours before anticipated sexual activity.

- The summary of product characteristics states that should not be used in men taking phosphodiesterase type 5 inhibitors (for example, sildenafil).

- The summary of product characteristics states that a careful appraisal of the individual benefit/risk ratio should be carried out after the first 4 weeks of treatment (or at least after 6 doses of treatment) with to determine whether continuing treatment is appropriate. If is continued the benefit/risk balance should be re-evaluated at least every 6 months.

- Men will need to balance the potential benefits with the likelihood of very common (greater than 1 in 10 men) adverse reactions of dizziness, headache and nausea reported in the summary of product characteristics.

is rapidely absorbed after oral ingestion with a maximum plasma concentration after 1–2 h. Bioavailability 15–76%, food has only a minimal influence. 99% plasma protein binding. is inactivated in the liver and kidneys by cytochrome (CYP2D6 and CYP3A4) and monooxygenases. The metabolites are excreted via the urine. Depending on the frequency of intake, the elimination half-life varies between less than one hour to 19 h.

Dosage 30 mg one to three hours before planned sexual activity. should only be taken once a day. In the case of inefficacy without side effects, the dosage may be increased to 60 mg.